Regenenron制药公司报告Q4产量强劲,收入增长10.3%,机构投资者满意。 Regeneron Pharmaceuticals reported a strong Q4 with a 10.3% revenue rise, pleasing institutional investors.

Regenenron制药公司看到一些机构投资者在第四季度调整了其持有量,Ledyard National Bank将其份额增加了2.1%,达到6 525个。 Regeneron Pharmaceuticals saw several institutional investors adjust their holdings in the fourth quarter, with Ledyard National Bank increasing its shares by 2.1% to 6,525. 生物制药公司的股票为83.31%,由机构投资者拥有。 The biopharmaceutical company's stock is 83.31% owned by institutional investors. Regeneron报告财务情况强劲,收入增长10.3%,达到37.9亿美元,每股收入12.07美元,超过了分析师的估计。 Regeneron reported strong financials, with a 10.3% increase in revenue to $3.79 billion and earnings per share of $12.07, surpassing analyst estimates. 分析师的“机动购买”评级为973.13美元,价格目标为973.13美元。 Analysts have a "Moderate Buy" rating with a price target of $973.13.